Nantes University Hospital: Leukemia trials

The registry lists 11 Leukemia studies with Nantes University Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 4Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT07392814Phase 1
• Study of NK Cells in the Monitoring of Patients With Acute Leukemia or MyelodysplasiaNot yet recruitingNCT07249476
• Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMRecruitingNCT05697510Phase 1
• Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04886206Phase 1
• Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute LeukemiaCompletedNCT02693899
• The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled StudyCompletedNCT02343965Not applicable
• Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Status unknownNCT01354457Phase 1/2
• Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)Status unknownNCT01146262Phase 1/2
• Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell TransplantationCompletedNCT01015196Phase 2/3
• Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskCompletedNCT00860639Phase 3
• Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT00724360Phase 2